SFI
MCRB icon

Susquehanna Fundamental Investments’s Seres Therapeutics MCRB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,649
Closed -$340K – 1368
2022
Q3 		$340K Buy
+2,649
New +$271K 0.01% 1123
2022
Q1 		$377K Sell
2,649
-1,303
-33% -$200K 0.01% 1178
2021
Q4 		$658K Buy
+3,952
New +$628K 0.02% 812

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Susquehanna Fundamental Investments's MCRB Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 2,649 shares — an estimated $340K sold.

Susquehanna Fundamental Investments first reported a position in MCRB in Q4 2021 and held it in 3 quarters. The position peaked at $658K in Q4 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

  • Susquehanna Fundamental Investments reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 2,649 Seres Therapeutics shares in Q4 2022, an estimated $340K.
  • Susquehanna Fundamental Investments first reported a position in Seres Therapeutics in Q4 2021 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Seres Therapeutics position peaked at $658K in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.